Navigation Links
Lentigen Appoints Jim Meade as Vice President of Corporate Development
Date:6/16/2008

BALTIMORE, June 16 /PRNewswire/ -- Lentigen Corporation today announced the appointment of Jim Meade, Ph.D., CLP, as vice president of corporate development. In addition to contributing to the strategic direction of the company, Dr. Meade will be responsible for managing the development of Lentigen's partnerships, stakeholder relations, product and intellectual property portfolios, contract negotiations, and other key aspects of corporate development.

Tim Ravenscroft, CEO of Lentigen, commented, "Jim's extensive background in strategic development, opportunity evaluation, and negotiation will be an important asset to Lentigen as we continue to advance our business opportunities and collaborative relationships in biotherapeutics, vaccines and protein production."

Dr. Meade previously worked at Avalon Pharmaceuticals, where he served as vice president of business development. With more than 30 years' experience in the pharmaceutical and biotechnology industries, he has also held senior-level positions at Pharmacia, Bayer and Chiron. He holds a Ph.D. in molecular biology from the University of Texas, and is a Certified Licensing Professional and an active member of the Licensing Executives Society.

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing lentiviral vector-based products across a broad spectrum of bench to clinical applications. Partnerships include The National Institutes of Health, The University of Pennsylvania, ThermoFisher Scientific and The U.S. Army. For further information, visit http://www.lentig
'/>"/>

SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
2. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
3. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
4. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
5. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
6. VIRxSYS and Lentigen Announce Litigation Settlement
7. NovaVision Appoints Medical Technology Veteran Rudy Mazzocchi as Chief Executive Officer
8. Applied Computational Technologies Appoints a New CEO
9. AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs
10. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
11. American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated (Nasdaq: ... committed to the fostering and monetization of intellectual ... VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  Spherix ... 3:13-cv-03496-M, both in the United States District Court ... . On November 21, ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Two new educational ... what comes next for ALS research and how the pharmaceutical ... After the Ice Bucket Challenge: Where Does the ALS Money ... Tuesday, 2 December 2014, Time: 1:30pm ET, Register ... expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology ...
(Date:11/22/2014)... Colo. (PRWEB) November 21, 2014 ... proprietary cloud based analytics and scientific testing methodologies relating ... commitment for a $750,000 line of credit from an ... extremely pleased to have secured this commitment from one ... Executive Officer of CannLabs. “This capital will help accelerate ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market by ... Glass, Plastic), by Application [GC, LC (HPLC, UHPLC, ... 2018” analyses and studies the major market drivers, ... Asia, and Rest of the World. , Browse ... through 135 pages and in-depth TOC on “Chiral ...
Breaking Biology Technology:Markman Hearing Held as Scheduled in VTech and Uniden Cases 2DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2CannLabs Secures $750,000 Line Of Credit 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... Inc. (Nasdaq: NVAX ) today announced that it ... press release to be issued after 8:00 a.m. Eastern Time ... investor conference call to discuss its financial results at 10:00 ... will be hosted by Novavax President and Chief Executive Officer ...
... May 4 The Arcas Group, a ... Stefan Terwindt, MBA as Executive Vice President. He will ... Terwindt previously served as President of Imedex, Inc."Stefan is ... and skills to our company," said Founder and President ...
... & Company, LLC, a Boston-based life science investment bank, ... has joined the firm as senior advisor. In ... on internal and client-related activities including private equity placements ... focus on medical device transactions. "We are thrilled ...
Cached Biology Technology:Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call 2The Arcas Group Appoints Executive Vice President 2Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company 2
(Date:11/4/2014)... 2014) – A majority of Madagascar,s 101 species of ... serious consequences for the rainforests they call home. A ... impacts lemurs can have on rainforest tree populations, which ... have on the region,s rich biodiversity. , A large ... by lemurs. Lemurs in turn disperse the seeds ...
(Date:11/3/2014)... Center study published in this month,s ... the activity of a recently discovered communication molecule of ... has been known to limit inflammation and the current ... IL-37 inhibits the ability of the immune system to ... that underlies IL-37,s effect on the immune system now ...
(Date:11/2/2014)... In this month,s issue of Physics World , ... bridging the "valley of death" to take their innovations ... argues that the gruelling challenge facing all start-up companies ... harder for physicists because of two main factors: physics-based ... and they often turn out to be a lot ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3PNAS: From HIV to cancer, IL-37 regulates immune system 2The 'valley of death' facing physics start-ups 2
... developed at the Hebrew University of Jerusalem that is ... led to approval by the U.S. Food and Drug ... cardiac surgery patients. The product is the ... biodegradable polymers for the prevention of post-surgical adhesions. SyntheMed ...
... available in German . , Helsinki/Leipzig. ... trading, will only be successful if they are coherently ... issues, says a report published today by the Partnership ... from seven of the biggest European environmental research institutes. ...
... Both plant and human diseases that can travel ... more rapidly than has been understood, according to a ... only for some human diseases but also a new ... done by scientists at Oregon State University and other ...
Cached Biology News:Hebrew University professor's work leads to FDA approval for product 2Climate change aims need to be better integrated 2New wheat disease could spread faster than expected 2New wheat disease could spread faster than expected 3